Want to see HK:2575 full AI Analyst Report?
2575 Stock Chart & Stats
HK$33.56
--
Market closed
HK$33.56
--
Day’s Range― - ―
52-Week RangeHK$12.61 - HK$96.90
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
HK$6.90B
Enterprise ValueHK$8.25B
Total Cash (Recent Filing)HK$216.62M
Total Debt (Recent Filing)HK$1.37M
Price to Earnings (P/E)―
Beta3.73
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding160,702,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio2.47
Price to Book (P/B)23.93
Price to Sales (P/S)650.34
P/FCF Ratio-163.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained strong top-line expansion across 2024–2025 signals meaningful commercial traction and expanding market adoption of the company’s products. Durable revenue scaling improves the odds of achieving operating leverage and supports reinvestment in R&D and commercialization over the medium term.
Improving Margins (gross Margin Turned Positive)A move to positive gross margin indicates improving unit economics and progress toward scalable profitability. If sustained, this structural improvement enables incremental revenue to flow more directly to operating leverage and increases the probability of future positive free cash flow as sales grow.
Conservative Balance Sheet With Low DebtLow leverage and rising equity/assets provide financial flexibility and reduce refinancing risk while the business scales. This conservative financing profile extends runway for R&D and commercialization, lowering the short-to-medium-term insolvency risk despite ongoing operating losses.
Bears Say
Persistent Operating And Net LossesRepeated operating and net losses show the business has not yet converted revenue growth into profit. Persistent losses erode shareholder value, limit internal funding capacity for expansion, and mean the company must prove durable profitability to justify continued investment and scale.
Negative Operating Cash Flow And Funding RelianceChronic negative operating and free cash flow forces dependence on external financing, increasing execution and dilution risk. Even with improved burn in 2025, the company needs to convert margin gains into positive cash generation to eliminate funding risk and sustain organic growth.
High Volatility / Elevated BetaA very high beta denotes pronounced share-price volatility and a higher implied cost of capital, which can complicate fundraising and reduce investor appetite for long-duration biotech investments. Elevated volatility raises execution risk for multi-quarter strategic initiatives.
Xuanzhu Biopharmaceutical Co., Ltd. Class H News
2575 FAQ
What was Xuanzhu Biopharmaceutical Co., Ltd. Class H’s price range in the past 12 months?
Xuanzhu Biopharmaceutical Co., Ltd. Class H lowest stock price was HK$12.61 and its highest was HK$96.90 in the past 12 months.
What is Xuanzhu Biopharmaceutical Co., Ltd. Class H’s market cap?
Xuanzhu Biopharmaceutical Co., Ltd. Class H’s market cap is HK$6.90B.
When is Xuanzhu Biopharmaceutical Co., Ltd. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Xuanzhu Biopharmaceutical Co., Ltd. Class H’s earnings last quarter?
Currently, no data Available
Is Xuanzhu Biopharmaceutical Co., Ltd. Class H overvalued?
According to Wall Street analysts Xuanzhu Biopharmaceutical Co., Ltd. Class H’s price is currently Overvalued.
Does Xuanzhu Biopharmaceutical Co., Ltd. Class H pay dividends?
Xuanzhu Biopharmaceutical Co., Ltd. Class H does not currently pay dividends.
What is Xuanzhu Biopharmaceutical Co., Ltd. Class H’s EPS estimate?
Xuanzhu Biopharmaceutical Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xuanzhu Biopharmaceutical Co., Ltd. Class H have?
Xuanzhu Biopharmaceutical Co., Ltd. Class H has 160,702,000 shares outstanding.
What happened to Xuanzhu Biopharmaceutical Co., Ltd. Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Xuanzhu Biopharmaceutical Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2575
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xuanzhu Biopharmaceutical Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-53.85%
Trailing 12-Months
Asset Growth
43.47%
Trailing 12-Months
Company Description
Xuanzhu Biopharmaceutical Co., Ltd. Class H
Xuanzhu Biopharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the research, production, and commercialization of both small-molecule chemical compounds and large-molecule biopharmaceuticals. The company's primary drug candidates include Core- KBP-3571, developed for treating duodenal ulcers; XZP-3287, a CDK4/6 inhibitor aimed at advanced HR+/HER2 breast cancer; and XZP-3621, intended as a first-line therapy for patients suffering from anaplastic lymphoma kinase-positive (ALK+) advanced non-small-cell lung cancer. Its development pipeline further encompasses KM501, a pioneering HER2/HER2 bispecific antibody drug conjugate currently in Phase I clinical trials, alongside KM602, another anti-tumor agent also undergoing Phase I evaluation. Other investigational assets include XZP-7797, a selective and brain-penetrating poly ADP-ribose polymerase 1 (PARP1) inhibitor; XZP-6924, which targets ubiquitin-specific protease 1 (USP1); XZB-0004, an oral small molecule anexelekto inhibitor; and XZP-6877, a DNA-dependent protein kinase inhibitor. The portfolio also features NG-350A, a next-generation oncolytic viral therapy; XZP-5610, a non-steroidal farnesoid X receptor; and XZP-6019, a first-in-class ketohexokinase (KHK) inhibitor. Founded in 2008 and headquartered in Beijing, China, Xuanzhu Biopharmaceutical Co., Ltd. operates as a subsidiary of Sihuan Pharm.
Technical Analysis
HUTCHMED (China)
―
Hua Medicine
―
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
―
Hansoh Pharmaceutical Group Company Limited
―
CanSino Biologics, Inc. Class H
―